Crystallization and preliminary X-ray analysis of the aromatic prenyltransferase CloQ from the clorobiocin biosynthetic cluster of Streptomyces roseochromogenes by Keller, Sascha et al.
crystallization communications
Acta Cryst. (2006). F62, 1153–1155 doi:10.1107/S1744309106042527 1153
Acta Crystallographica Section F
Structural Biology
and Crystallization
Communications
ISSN 1744-3091
Crystallization and preliminary X-ray analysis of the
aromatic prenyltransferase CloQ from the
clorobiocin biosynthetic cluster of Streptomyces
roseochromogenes
Sascha Keller,
a Florence Pojer,
b‡
Lutz Heide
b and David M.
Lawson
a*
aDepartment of Biological Chemistry,
John Innes Centre, Norwich NR4 7UH, England,
and
bUniversita ¨tT u ¨bingen, Pharmazeutische
Biologie, Auf der Morgenstelle 8,
72076 Tu ¨bingen, Germany
‡ Present address: The Jack H. Skirball Center
for Chemical Biology and Proteomics, The Salk
Institute for Biological Studies, 10010 North
Torrey Pines Road, La Jolla, CA 92037, USA
Correspondence e-mail:
david.lawson@bbsrc.ac.uk
Received 5 October 2006
Accepted 13 October 2006
Crystals of recombinant CloQ (subunit MW = 35 626 Da; 324 amino acids), an
aromatic prenyltransferase from Streptomyces roseochromogenes, were grown
by vapour diffusion. The protein crystallizes in space group I4122, with unit-cell
parameters a = b = 135.19, c = 98.13 A ˚ . Native data from a single crystal were
recorded to a resolution of 2.2 A ˚ in-house. Preliminary analysis of these data
indicated that the asymmetric unit corresponds to a monomer, giving an
estimated solvent content of 60.6%. CloQ is involved in the biosynthesis of the
aminocoumarin antibiotic clorobiocin, which targets the essential bacterial
enzyme DNA gyrase.
1. Introduction
Streptomycetes are responsible for over two-thirds of the naturally
derived antibiotics in clinical use today (Bentley et al., 2002). How-
ever, the widespread and often inappropriate use of these compounds
has led to an alarming increase in the number of bacterial strains that
have become resistant to them. Thus, there is a continual need to
develop new antibiotics. To this end, we are studying the biosynthesis
of a class of antibiotics termed the aminocoumarins, which are natural
products of streptomycetes. There are three main compounds,
novobiocin, clorobiocin and coumermycin A1, that are synthesized by
enzymes encoded in the nov, clo and cou gene clusters, respectively
(Steffensky et al., 2000; Wang et al., 2000; Pojer et al., 2002). They all
share common structural features: a 3-amino-4,7-dihydroxycoumarin
ring, an l-noviosyl sugar and an aromatic acyl component attached to
the amino group of the aminocoumarin moiety. These compounds are
potent inhibitors of DNA gyrase (Gellert et al., 1976), an essential
enzyme in bacteria and a validated drug target (Maxwell, 1997;
Maxwell & Lawson, 2003). However, they have not seen widespread
clinical application onaccount of their low solubility, poor uptake and
eukaryotic cell toxicity. Using a combination of structural and
mechanistic approaches, we aim to inform the rational redesign of
these compounds through the manipulation of the individual
enzymes in the pathways. We report here the crystallization and
preliminary X-ray analysis of CloQ, an aromatic prenyltransferase
from Streptomyces roseochromogenes that is responsible for attaching
a dimethylallyl unit to the hydroxybenzoic acid moiety of clorobiocin
(Pojer et al., 2003).
2. Materials and methods
2.1. Protein expression and purification
The cloQ coding sequence (UniProtKB/TrEMBL entry Q8GHB2)
was ampliﬁed by PCR using as a template the K1F2 cosmid (Pojer et
al., 2002) containing the complete clorobiocin biosynthetic gene
cluster. The PCR product was cloned into pET28a (Novagen),
resulting in an expression construct encoding for CloQ with a
thrombin-cleavable N-terminal hexahistidine tag. This added a
further 20 residues to the native protein (with sequence
MGSSHHHHHHSSGLVPRGSH), giving a total deduced molecular
weight of 37 790 Da. In order to maximize the yield of soluble
protein, the plasmid containing the cloQ gene was co-transformed
with plasmid pGroESL-911 encoding the GroES/GroEL chaperone
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1986). For protein expression, 10 ml of an overnight culture of these
cells was used to inoculate 1 l Luria–Bertani medium containing
50 mg kanamycin and 5 mg tetracycline. The cells were grown at
310 K to an OD600 of around 0.4. The culture was then cooled to
293 K, induced by the addition of isopropyl  -d-thiogalactopyrano-
side to a ﬁnal concentration of 0.5 mM and shaken for an additional
5 h at 293 K. The cells were harvested by centrifugation in a Sorvall
Evolution centrifuge (10 min, 7000 rev min
 1, 277 K, SLC-6000
rotor) and stored at 253 K until further puriﬁcation.
The cell pellet was subsequently resuspended in buffer A [50 mM
Tris–HCl pH 8.0, 500 mM NaCl, 30 mM imidazole, 10%(v/v) glycerol,
10 mM  -mercaptoethanol] containing 1%(v/v) Tween 20 and lysed
by two passes through a French press (6.9 MPa, 277 K). The cell
debris was removed by centrifugation in a Sorvall RC5C centrifuge
(30 min, 19 000 rev min
 1, 277 K, SS34 rotor) and the supernatant
was applied onto a pre-equilibrated 1 ml Ni
2+-charged His-Trap
Chelating HP column (GE Healthcare). The column was then washed
with ten column volumes (CV) of buffer A and the bound protein was
eluted over 10 CV in a linear gradient to 1 M imidazole in buffer A.
The fractions containing the CloQ protein (conﬁrmed by SDS–
PAGE) were pooled and dialysed at 277 Kovernight against 2 l buffer
B [50 mM Tris–HCl pH 8.0, 150 mM NaCl, 2 mM CaCl2,5 m M
dithiotreitol (DTT)]. Subsequently, the N-terminal His tag was
cleaved using thrombin (Sigma). The cleavage site lies after the ﬁnal
Arg of the tag,leaving just three residues of the linker (i.e. GSH). The
resulting 327-residue protein, which we shall refer to as GSH-CloQ,
would have a calculated molecular weight of 35 908 Da. For cleavage,
the CloQ protein was diluted to 100 mM in buffer B and incubated for
at least 5 h at 277 K in the presence of thrombin at a concentration of
0.3 U per milligram of CloQ protein. The completeness of the
cleavage reaction was conﬁrmed by SDS–PAGE. For ﬁnal puriﬁca-
tion, the protein was applied onto a Superdex 75 HiLoad HP gel-
ﬁltration column (GE Healthcare) pre-equilibrated in buffer B
without CaCl2. The elution fractions containing CloQ were pooled
and concentrated to around 10 mg ml
 1 using an Amicon Ultra-4
10 kDa cutoff concentrator (Millipore).
Prior to crystallization, dynamic light scattering (DLS) was used to
monitor the solution properties of the protein. For this purpose,
approximately 30 ml sample was centrifuged through a 0.1 mm
Ultrafree-MC ﬁlter (Millipore) to remove particulate material before
introduction into the 12 ml microsampling cell of a Dynapro-MSTC
molecular-sizing instrument (Protein Solutions Inc.). A minimum of
20 scattering measurements were taken at 277 and 293 K and the
resulting data were analysed using theDYNAMICS software package
(Protein Solutions Inc.).
2.2. Crystallization and X-ray data collection
Crystallization screening trials were carried out by vapour diffu-
sion in a sitting-drop format in 96-well Greiner plates using a variety
of in-house and commercially available screens (Hampton Research
and Nextal) at constant temperatures of 293 and 277 K. Drops
consisted of 1 ml protein solution mixed with 1 ml well solution and
the well volume was 100 ml. The protein concentration was approxi-
mately 10 mg ml
 1. Trials were performed both with and without
4-hydroxyphenylpyruvate (HPP), a substrate of CloQ (Pojer et al.,
2003), at a concentration of 2 mM. Improved crystals were subse-
quently obtained by reﬁning the successful conditions from the initial
screens and adapting them to a hanging-drop format using 24-well
VDX plates (Hampton Research). In this case, the well volume was
increased to 1 ml.
Prior to cryogenic data collection, crystals were given a brief soak
(<30 s) in cryoprotectant, which corresponded to the crystallization
solution supplemented with 25%(w/v) xylitol in place of an equiva-
lent volume of buffer. Crystals were routinely transferred from one
solution to another and ultimately mounted for X-ray data collection
using cryo-loops (Hampton Research). They were ﬂash-cooled to
100 K in a stream of gaseous nitrogen produced by an X-Stream
cryocooler (Rigaku-MSC). Diffraction data were collected in-house
using a MAR 345 image-plate detector (X-ray Research) mounted on
a Rigaku RU-H3RHB rotating-anode X-ray generator (operated at
50 kV and 100 mA) ﬁtted with Osmic confocal optics and a copper
target (Cu K ;   = 1.542 A ˚ ). The diffraction data were integrated
using MOSFLM (Leslie, 2006) and scaled using SCALA (Evans,
2006). Further analysis of the data was performed using programs
from the CCP4 suite (Collaborative Computational Project, Number
4, 1994).
3. Results and discussion
CloQ was overexpressed and puriﬁed with a ﬁnal yield of approxi-
mately 2 mg of protein from 1 l culture and was judged to be greater
than 98% pure by SDS–PAGE analysis. The DLS analysis gave a
monomodal distribution, with a polydispersity of 26%. From these
results, the molecular size was estimated at 39.9 kDa, being close to
the value expected for a GSH-CloQ monomer (i.e. 35.9 kDa).
Although there was no signiﬁcant difference in the DLS results
obtained at 277 and 293 K, CloQ protein of this quality could only
been obtained if the temperature was strictly maintained at 277 K
during the puriﬁcation process.
Preliminary crystals were obtained within 48 h at 293 K from
several conditions containing at least 3.5 M sodium formate.
Improved crystals were subsequently obtained by reducing the
temperature of the crystallization to 277 K with a precipitant solution
consisting of 3.0 M sodium formate in 100 mM HEPES pH 7.0.
Further improvements were seen when 2 mM HPP was used in all
buffer solutions during puriﬁcation, resulting in large single crystals
with dimensions up to 300   200   50 mm (Fig. 1). Simply adding
HPP to the protein solution prior to crystallization did not have the
same positive effect.
Native X-ray data were collected in-house from a single CloQ
crystal: a total of 200   0.5  oscillation images were recorded in a
continuous sweep to a maximum resolution of 2.2 A ˚ . Indexing was
consistent with an I-centred tetragonal lattice, with unit-cell para-
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Figure 1
Single crystals of S. roseochromogenes CloQ approximately 300   200   50 mmi n
size.meters a = b = 135.19, c= 98.13 A ˚ . After processing the data in space
group I4, pseudo-precession plots were analysed using HKLVIEW
(Collaborative Computational Project, Number 4, 1994). These
strongly suggested that the symmetry was actually I422 and the
systematic absences were indicative of space group I4122. Repro-
cessing in this space group yielded a data set that was 97.3% complete
to 2.2 A ˚ resolution. Data-collection statistics are summarized in
Table 1. Estimation of the content of the asymmetric unit based on a
single GSH-CloQ molecule gave a crystal-packing parameter (VM)o f
3.12 A ˚ 3 Da
 1, with a corresponding solvent content of 60.6%
(Matthews, 1968).
The Protein Data Bank (PDB; Berman et al., 2000) was inter-
rogated for potential molecular-replacement templates using the
amino-acid sequence of CloQ. Only one suitable candidate was
retrieved, namely Orf2, a prenyltransferase from Streptomyces sp.
strain CL190 (PDB code 1zb6). Orf2 has a novel barrel fold, termed a
PT barrel, which superﬁcially resembles the canonical TIM barrel but
has a distinctly different connectivity (Kuzuyama et al., 2005).
However, the CLUSTALW alignment server (Chenna et al., 2003)
aligned only two-thirds of the CloQsequence with that of Orf2, with a
relatively low sequence identity of 22%. A molecular-replacement
search model was subsequently created using the program
CHAINSAW (Collaborative Computational Project, Number 4,
1994) with reference to this alignment: the sequence of the Orf2
monomer structure was ‘mutated’ to that of CloQ and any non-
aligned regions were deleted from the structure. In addition, all water
molecules, metal ions and other ligands were stripped from the
model. Molecular replacement was performed with the programs
AMoRe (Navaza, 1994), MOLREP (Vagin & Teplyakov, 2000) and
Phaser (McCoy et al., 2005) using this monomer template. Unfortu-
nately, no plausible solutions were obtained in any of the programs,
although this is not too surprising given the low sequence identity
between CloQ and Orf2. Therefore, we will need to solve the CloQ
structure by isomorphous replacement methods. To this end, we are
currently preparing selenomethionine-labelled protein: there are a
total of six methionine residues present in the 324-amino-acid
sequence of CloQ.
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Table 1
Summary of X-ray data for CloQ.
Values in parentheses are for the outer resolution shell
Wavelength (A ˚ ) 1.542
Resolution range (A ˚ ) 31.86–2.21 (2.33–2.21)
Unique reﬂections 22556 (2718)
Completeness (%) 97.3 (81.6)
Redundancy 7.7 (7.3)
Rmerge† 0.084 (0.301)
hI/ (I)i 19.6 (7.3)
Wilson B factor (A ˚ 2) 24.4
† Rmerge =
P
h
P
l jIhl  h Ihij=
P
h
P
lhIhi, where Il is the lth observation of reﬂection h
and hIhi is the weighted average intensity for all observations l of reﬂection h.